Clinical Study for Inhibition of Intimal Hyperplasia : Past & Present.
- Author:
Byung Gon NA
1
;
Jung Hwan JANG
Author Information
1. Department of Surgery, College of Medicine, Chosun University, Gwangju, Korea. jhchang@chosun.ac.kr
- Publication Type:Review ; Clinical Trial
- Keywords:
Intimal hyperplasia;
Restenosis
- MeSH:
Angioplasty, Balloon;
Brachytherapy;
Human Body;
Hyperplasia;
Stents
- From:Journal of the Korean Society for Vascular Surgery
2008;24(2):155-162
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
INTRODUCTION: Intimal hyperplasia can be considered as a physiological reaction to the intravascular injury which occurs spontaneously in human body. But the fact that we can not block the intimal hyperplasia completely so far when there is any form of stimuli, can be thought to be as a result of not understanding thoroughly the pathological phenomenon about it. SUBJECT: There are many drugs, radiation therapies, stent, genetic treatment. Pharmacologic treatment with several drugs have been trided and most of them have all failed. Vascular brachytherapy resulted in no inhibition of restenosis. Stent is preferred to balloon angioplasty because of good patency. Genetic treatment is limited due to other E2F analogue. CONCLUSION: Although it is too early to predict the outcome of inhibition of intimal hyperplasia trials, these fundamental studies provide great evidences and hope that these clinical trials for inhibition of restenosis will eventually become effective option.
